Correlation of CD95 and soluble CD95 expression with acute rejection status of liver transplantation

World Journal of Gastroenterology

Volumn 11, Issue 11, 2005, Pages 1700-1704

  Wang, Yu Liang ^a   Zhang, Yan Yan ^b   Li, Guang ^c   Tang, Zhi Qin ^a   Zhou, Yan Li ^d   Zhu, Zhi Jun ^a   Yao, Zhi ^c  

^a TIANJIN FIRST CENTRAL HOSPITAL   (China)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Acute rejection; CD95; Liver transplantation

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; DACLIZUMAB; FAS ANTIGEN; FAS LIGAND; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT INFECTION; HUMAN; HUMAN CELL; IMMUNE STATUS; LIVER CELL; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; QUANTITATIVE ANALYSIS; RECIPIENT; SEROLOGY; T LYMPHOCYTE; VOLUNTEER;

EID: 17144367023     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i11.1700     Document Type: Article

References (35)

1. Gupta RK, Jain M, Sharma RK. Serum urinary interleukin-2 levels as predictors in acute renal allograft rejection. Indian J Med Res 2004; 119: 24-27
2. Wang YL, Tang ZQ, Gao W, Jiang Y, Zhang XH, Peng L. Influence of Th1, Th2, and Th3 cytokines during the early phase after liver transplantation. Transplant Proc 2003; 35: 3024-3025
3. Bathgate AJ, Lee P, Hayes PC, Simpson KJ. Pretransplantation tumor necrosis factor-alpha production predicts acute rejection after liver transplantation. Liver Transpl 2000; 6: 721-727
4. Drannik GN, Lunova AG, Baran YY, Poroshina TV, Kalinina NA. Cytokine producing function of type II T-helpers in transplanted kidney patients. Transplant Proc 2001; 33: 2352-2354
5. Radvanyi LG, Mills GB, Miller RG. Religation of the T cell receptor after primary activation of mature T cells inhibits proliferation and induces apoptotis cell death. J Immunol 1993; 150: 5704-5715
6. Wesselborg S, Janssen O, Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol 1993; 150: 4338-4345
7. Lai JH, Ho LJ, Lu KC, Chang DM, Shaio MF, Han SH. Western and Chinese antirheumatic drug-induced T cell apoptotic DNA damage uses different caspase cascades and is independent of Fas/Fas ligand interaction. J Immunol 2001; 166: 6914-6924
8. Pettersen RD, Bernard G, Olafsen MK, Pourtein M, Lie SO. CD99 signals caspase-independent T cell death. J Immunol 2001; 166: 4931-4942
9. Kanzler S, Galle PR. Apoptosis and the liver. Semin Cancer Biol 2000; 10: 173-184
10. Boussiotis VA, Lee BJ, Freeman GJ, Gribben JG, Nadler LM. Induction of T cell clonal energy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death. J Immunol 1997; 159: 3156-3167
11. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456
12. Sacco R, Leuci D, To Ytorella C, Fiore G, Marinosci F, Schiraldi O, Antonaci S. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma. Cytokine 2000; 12: 811-814
13. Bijl M, Horst G, Limburg PC, Kallenberg CG. Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): Relation to lymphocyte activation and disease activity. Lupus 2001; 10: 866-872
14. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S. Fas ligand in human serum. Nature Med 1996; 2: 317-322
15. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998; 4: 31-36
16. Krensky AM, Weiss A, Crabtree G, Davis MM, Parham P. T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 1990; 322: 510-517
17. Zavazava N, Kabelitz D. Alloreactivity and apoptosis in graft rejection and transplantation tolerance. J Leukoc Biol 2000; 68: 167-174
18. Rivero M, Crespo J, Mayorga M, Fabrega E, Casafont F, Pons-Romero F. Involvement of the Fas system in liver allograft rejection. Am J Gastroenterol 2002; 97: 1501-1506
19. Di Renzo M, Capecchi PL, Camurri A, Di Ciolla F, Maccherini M, Lisi G, Pompella G, Pasqui AL, Auteri A, Abbracchio MP, Pasini FL. Enhanced apoptosis of peripheral blood mononuclear cells in cardiac transplanted patients undergoing chronic immunosuppressive treatment. Transpl Immunol 2002; 10: 269-275
20. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995; 181: 71-77
21. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373: 444-448
22. Bonfoco E, Stuart PM, Brunner T, Lin T, Griffith TS, Gao Y, Nakajima H, Henkart PA, Ferguson TA, Green DR. Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. Immunity 1998; 9: 711-720
23. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF, Green DR. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995; 373: 441-444
24. Seino K, Kayagaki N, Bashuda H, Okumura K, Yagita H. Contribution of Fas ligand to cardiac allograft rejection. Int Immunol 1996; 8: 1347-1354
25. Josien R, Muschen M, Gilbert E, Douillard P, Heslan JM, Soulillou JP, Cuturi MC. Fas ligand, tumor necrosis factor-alpha expression, and apoptosis during allograft rejection and tolerance. Transplantation 1998; 66: 887-893
26. Crespo J, Rivero M, Mayorga M, Fabrega E, Casafont F, Gomez-Fleitas M, Pons-Romero F. Involvement of the Fas system in hepatitis C virus recurrence after liver transplantation. Liver Transpl 2000; 6: 562-569
27. Ryo K, Kamogawa Y, Ikeda I, Yamauchi Y, Yonehara S, Nagata S, Hayashi N. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Am J Gastroenterol 2000; 95: 2047-2055
28. Iio S, Hayashi N, Mita E, Ueda K, Mochizuki K, Hiramatsu N, Kanto T, Sasaki Y, Kasahara A, Hori M. Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol 1998; 29: 517-523
29. Hamzaoui K, Hamzaoui A, Zakraoui L, Chabbou A. Levels of soluble Fas/APO-1 in patients with Behcet's disease. Mediators Inflamm 1998; 7: 111-114
30. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 1997; 40: 1126-1129
31. Sharma VK, Bologa RM, Li B, Xu GP, Lagman M, Hiscock W, Mouradian J, Wang J, Serur D, Rao VK, Suthanthiran M. Molecular executors of cell death-differential intrarenal expression of Fas ligand, Fas, granzyme B, and perforin during acute and/or chronic rejection of human renal allografts. Transplantation 1996; 62: 1860-1866
32. + lymphocytes augment chronic rejection in a MHC class II mismatched model. Transplantation 2001; 71: 1146-1153
33. + T cells are critical for corneal, but not skin, allograft rejection. Transplantation 2000; 69: 483-487
34. Sadeghi M, Daniel V, Weimer R, Wiesel M, Hergesell O, Opelz G. Pre-transplant Th1 and post-transplant Th2 cytokine patterns are associated with early acute rejection in renal transplant recipients. Clin Transplant 2003; 17: 151-157
35. Chklovskaia E, Nowbakht P, Nissen C, Gratwohl A, Bargetzi M, Wodnar-Filipowicz A. Reconstitution of dendritic and natural killer-cell subsets after allogeneic stem cell transplantation: Effects of endogenous flt3 ligand. Blood 2004; 103: 3860-3868